3 min read
The Long View
The Long View: The Science Works, But Can We Scale It?
The science of personalised medicine works. Trikafta generates $8bn a year. Intismeran autogene has its Phase III win. The factory, the regulatory framework and the payment model are still playing catch-up.
More from this edition
The Long View: Big Pharma’s Obesity Shopping Moves Beyond The Incretin
Capsul Desk
6 min read
members
The Long View: When The First Reader Is A Machine
Lucie Ellis-Taitt
4 min read
members
The Long View: The AI Mountain Has Rules
Aakash Babu
4 min read
members
The Long View: Imcivree Outgrew Its Lock
Capsul Desk
5 min read
members
The Long View: After 11 Years, 2 Months, 23 Days and One $62bn Deal, Weber Hands Takeda to Kim
Christophe Weber leaves a global top-ten drugmaker, and the debt it took to get there. The verdict now belongs to the executive who arrived in the very transaction that made it.
Capsul Desk
7 min read
members